|

Zongertinib Clinical Trials

3 actively recruiting trials across 3 locations

No change since May 2026

Also known as: BI 1810631, Hernexeos®

Pipeline

Phase 2: 1Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Boehringer Ingelheim3

Indications

  • Cancer3
  • Metastatic Gastric Adenocarcinoma1
  • Gastroesophageal Junction Adenocarcinoma1
  • Metastatic Breast Cancer1
  • Esophageal Adenocarcinoma1

Anchorage, Alaska1 trial

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Alaska Oncology and Hematology, LLC

Phase 2

Phoenix, Arizona1 trial

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Mayo Clinic-Arizona

Phase 1/2

Fresno, California1 trial

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

ClinRé 001-022 (Premier Cancer Care and Infusion Center)

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.